We performed Chromatin Immunoprecipitation and Sequencing (ChIP-Seq) using an antibody against the TFE3 fusion in three tRCC cell lines (FU-UR-1, ASPL-TFE3 fusion; s-TFE, ASPL-TFE3 fusion; UOK109, NONO-TFE3 fusion) and called high-confidence genomic binding sites (Methods and Table S2). This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.